This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

MRI in Evaluating the Effect of Efaproxiral on the Brain in Patients With Recurrent or Progressive Glioma Enrolled on Clinical Trial NABTT-9806

This study has been withdrawn prior to enrollment.
(not enough interest)
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00433472
First received: February 8, 2007
Last updated: July 27, 2015
Last verified: July 2015
  Purpose

RATIONALE: Diagnostic procedures, such as MRI, may help doctors learn how efaproxiral works in the brain and help plan the best treatment.

PURPOSE: This clinical trial is using MRI to evaluate the effect of efaproxiral on the brain in patients with recurrent or progressive glioma receiving treatment on clinical trial NABTT-9806.


Condition Intervention
Brain and Central Nervous System Tumors Device: magnetic resonance imaging (MRI)

Study Type: Interventional
Study Design: Primary Purpose: Diagnostic
Official Title: Effect of RSR13 on T2 and T2* Cranial MRI Images: An Imaging Companion Study to NABTT 9806

Resource links provided by NLM:


Further study details as provided by Sidney Kimmel Comprehensive Cancer Center:

Primary Outcome Measures:
  • Measurable effect of efaproxiral on the brain as measured by T2 and/or T2* MRI
  • Predicted oxygenation changes based on observed T2 MRI changes
  • Effects of efaproxiral on T2 and T2* MRI relaxation times of normal areas of the brain
  • Baseline oxygen extraction ratios in tumors
  • New tumor- or non-tumor-related abnormalities on T2 and T2* MRI

Enrollment: 0
Arms Assigned Interventions
MRI -

MRI scan to be complete to look at RSR13 on measurement of T2 and T2* on MRI

Procedure/surgery magnetic resonance imaging (MRI)

Device: magnetic resonance imaging (MRI)
MRI scan to be complete to look at RSR13 on measurement of T2 and T2* on MRI
Other Name: MRI

Detailed Description:

OBJECTIVES:

  • Determine whether efaproxiral has a measurable effect on the brain as shown by T2 and/or T2* MRI in patients with recurrent or progressive malignant glioma enrolled on NABTT-9806.
  • Determine predicted oxygenation changes based on observed T2 MRI changes in these patients.
  • Determine the effects of this drug on T2 and T2* MRI relaxation times of normal areas of the brain in these patients.
  • Determine baseline oxygen extraction ratios in tumors of patients treated with this drug.
  • Determine whether administration of this drug reveals any new tumor- or non-tumor-related abnormalities on T2 and T2* MRI in these patients.

OUTLINE: This is an open-label, multicenter, pilot study.

Patients receive efaproxiral and carmustine on clinical trial NABTT-9806. During any one course of treatment on that study, patients undergo MRI before oxygen administration (baseline), before efaproxiral infusion, and then every 5 minutes until 1 hour after efaproxiral and carmustine treatment. Data is evaluated for extent and intensity of T2/T2* changes and oxygen concentration changes in both abnormal and normal brain.

PROJECTED ACCRUAL: A total of 15-48 patients will be accrued for this study within 12-24 months.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Recurrent or progressive glioma
  • Currently enrolled on clinical trial NABTT-9806

PATIENT CHARACTERISTICS:

  • No severe claustrophobia
  • No cardiac pacemaker
  • No MRI-incompatible metallic implant

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00433472

Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center
National Cancer Institute (NCI)
Investigators
Study Chair: Larry Kleinberg, MD Sidney Kimmel Comprehensive Cancer Center
  More Information

Responsible Party: Joy Fisher, ABTC Consortium
ClinicalTrials.gov Identifier: NCT00433472     History of Changes
Other Study ID Numbers: NABTT-2002 CDR0000274785
U01CA062475 ( U.S. NIH Grant/Contract )
P30CA006973 ( U.S. NIH Grant/Contract )
NABTT-2002
JHOC-NABTT-2002
ALLOS-RSR13CT-001i
Study First Received: February 8, 2007
Last Updated: July 27, 2015

Keywords provided by Sidney Kimmel Comprehensive Cancer Center:
adult anaplastic oligodendroglioma
adult giant cell glioblastoma
adult anaplastic astrocytoma
recurrent adult brain tumor
adult glioblastoma
adult gliosarcoma

Additional relevant MeSH terms:
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms by Site
Neoplasms
Nervous System Diseases

ClinicalTrials.gov processed this record on August 18, 2017